BGC515 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, there is a mention of an 'inadequate wash-out of prior therapies,' which suggests that some medications might need to be stopped before participating. It's best to discuss your specific medications with the trial team.
How does the drug BGC515 differ from other treatments for bladder cancer?
The research does not provide specific information about BGC515, but it highlights the potential of targeting CD155 in bladder cancer treatment, which is a novel approach compared to traditional therapies. This suggests that BGC515 might involve a unique mechanism related to CD155 targeting, setting it apart from existing treatments.12345
Are You a Good Fit for This Trial?
This trial is for patients with advanced solid tumors, including specific types such as Epithelioid Hemangioendothelioma and Mesothelioma. Participants must meet certain health standards to be eligible.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
BGC515 Capsules administered orally in 21 day cycles, once daily, to determine the Maximum Tolerated Dose (MTD) and Recommended Dose(s) for Expansion (RDE)
Dose Expansion
BGC515 Capsules administered orally in 21 day cycles at MTD/RDE defined dose, once daily, in patients with specific advanced solid tumors
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BGC515
Find a Clinic Near You
Who Is Running the Clinical Trial?
BridGene Biosciences Inc.
Lead Sponsor